ERBB2 and breast carcinoma: To address our research question, we used the anti-HER2 antibody trastuzumab and determined the cytotoxic potential of IL-2-activated, donor-derived NK cells in breast cancer models in the presence of hypoxia, an immunosuppressive factor frequently present in solid tumors.